JARDIANCE®
Empagliflozin
Resources
Browse our engaging and informative collection of resources to learn more about JARDIANCE® (empagliflozin) including practical tips on prescribing.
Quick links
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection (TA929) and reduced ejection fraction (TA773)
Indications
Heart failure
JARDIANCE® is indicated in adults for the treatment of symptomatic chronic heart failure.1
Type 2 diabetes
JARDIANCE® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance
- in addition to other medicinal products for the treatment of diabetes 1
According to the 5.1 section of the SmPC, both improvement of glycaemic control and reduction of cardiovascular morbidity and mortality are an integral part of the treatment of type 2 diabetes.1
Chronic kidney disease
JARDIANCE® is indicated in adults for the treatment of chronic kidney disease.1
Indications
Heart failure
JARDIANCE® is indicated in adults for the treatment of symptomatic chronic heart failure.1
Type 2 diabetes
JARDIANCE® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance
- in addition to other medicinal products for the treatment of diabetes 1
According to the 5.1 section of the SmPC, both improvement of glycaemic control and reduction of cardiovascular morbidity and mortality are an integral part of the treatment of type 2 diabetes.1
Chronic kidney disease
JARDIANCE® is indicated in adults for the treatment of chronic kidney disease.1
Downloadable resources for healthcare professionals in their management of heart failure patients
JARDIANCE Initiation & Management guide for T2D, CHF and CKD
Downloadable patient booklets for healthcare professionals to offer to their patients
HF patient booklet
Video resources
These videos were developed, organised and funded by the Boehringer Ingelheim and Lilly Alliance.
Watch Dr Jarvis and Dr Javaid discuss JARDIANCE in the treatment of adults with symptomatic chronic HFrEF
February 2024
4:48 m
How to prescribe JARDIANCE® for your adult patients with symptomatic chronic heart failure
February 2024
1:44 m
How did JARDIANCE® become a medication that can be used to improve cardiovascular outcomes in patients with type 2 diabetes with cardiovascular disease and managing heart failure?
February 2024
2:40 m
PC-GB-109303 V3
May 2024